| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10965445 | Vaccine | 2014 | 4 Pages |
Abstract
EVRI will be launched in three phases: preparatory (during which the legal and administrative framework will be defined and a business plan will be elaborated), implementation and operational. If sufficient political and financial commitment can be secured from relevant national and European entities as well as from the private sector and other stakeholders, it could enter into operational phase from 2017 onwards. In conclusion, EVRI can make vaccine R&D more efficient and help address European and global health challenges, help alleviate the burden and spread of infectious diseases, thus contributing to the sustainability of public healthcare systems.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Odile Leroy, Mark Geels, Joanna Korejwo, Betty Dodet, Nathalie Imbault, Stefan Jungbluth,